From Infection to Immunity: Understanding the Response to SARS-CoV2 Through
COVID-19
SARS-CoV-2
immunosenescence
in-silico modeling
virtual cohort
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
12
2020
accepted:
09
08
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
2
10
2021
Statut:
epublish
Résumé
Immune system conditions of the patient is a key factor in COVID-19 infection survival. A growing number of studies have focused on immunological determinants to develop better biomarkers for therapies. Studies of the insurgence of immunity is at the core of both SARS-CoV-2 vaccine development and therapies. This paper attempts to describe the insurgence (and the span) of immunity in COVID-19 at the population level by developing an in-silico model. We simulate the immune response to SARS-CoV-2 and analyze the impact of infecting viral load, affinity to the ACE2 receptor, and age in an artificially infected population on the course of the disease. We use a stochastic agent-based immune simulation platform to construct a virtual cohort of infected individuals with age-dependent varying degrees of immune competence. We use a parameter set to reproduce known inter-patient variability and general epidemiological statistics. By assuming the viremia at day 30 of the infection to be the proxy for lethality, we reproduce in-silico several clinical observations and identify critical factors in the statistical evolution of the infection. In particular, we evidence the importance of the humoral response over the cytotoxic response and find that the antibody titers measured after day 25 from the infection are a prognostic factor for determining the clinical outcome of the infection. Our modeling framework uses COVID-19 infection to demonstrate the actionable effectiveness of modeling the immune response at individual and population levels. The model developed can explain and interpret observed patterns of infection and makes verifiable temporal predictions. Within the limitations imposed by the simulated environment, this work proposes quantitatively that the great variability observed in the patient outcomes in real life can be the mere result of subtle variability in the infecting viral load and immune competence in the population. In this work, we exemplify how computational modeling of immune response provides an important view to discuss hypothesis and design new experiments, in particular paving the way to further investigations about the duration of vaccine-elicited immunity especially in the view of the blundering effect of immunosenescence.
Sections du résumé
Background
Immune system conditions of the patient is a key factor in COVID-19 infection survival. A growing number of studies have focused on immunological determinants to develop better biomarkers for therapies.
Aim
Studies of the insurgence of immunity is at the core of both SARS-CoV-2 vaccine development and therapies. This paper attempts to describe the insurgence (and the span) of immunity in COVID-19 at the population level by developing an in-silico model. We simulate the immune response to SARS-CoV-2 and analyze the impact of infecting viral load, affinity to the ACE2 receptor, and age in an artificially infected population on the course of the disease.
Methods
We use a stochastic agent-based immune simulation platform to construct a virtual cohort of infected individuals with age-dependent varying degrees of immune competence. We use a parameter set to reproduce known inter-patient variability and general epidemiological statistics.
Results
By assuming the viremia at day 30 of the infection to be the proxy for lethality, we reproduce in-silico several clinical observations and identify critical factors in the statistical evolution of the infection. In particular, we evidence the importance of the humoral response over the cytotoxic response and find that the antibody titers measured after day 25 from the infection are a prognostic factor for determining the clinical outcome of the infection. Our modeling framework uses COVID-19 infection to demonstrate the actionable effectiveness of modeling the immune response at individual and population levels. The model developed can explain and interpret observed patterns of infection and makes verifiable temporal predictions. Within the limitations imposed by the simulated environment, this work proposes quantitatively that the great variability observed in the patient outcomes in real life can be the mere result of subtle variability in the infecting viral load and immune competence in the population. In this work, we exemplify how computational modeling of immune response provides an important view to discuss hypothesis and design new experiments, in particular paving the way to further investigations about the duration of vaccine-elicited immunity especially in the view of the blundering effect of immunosenescence.
Identifiants
pubmed: 34557181
doi: 10.3389/fimmu.2021.646972
pmc: PMC8453017
doi:
Substances chimiques
Antibodies, Viral
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
646972Informations de copyright
Copyright © 2021 Castiglione, Deb, Srivastava, Liò and Liso.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Infect Dis. 2020 Jul 29;20(1):549
pubmed: 32727456
Nat Rev Mol Cell Biol. 2000 Oct;1(1):72-6
pubmed: 11413492
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1105-1110
pubmed: 28096374
Front Immunol. 2012 Sep 17;3:287
pubmed: 23060876
Science. 1959 Jun 19;129(3364):1649-53
pubmed: 13668512
Trends Immunol. 2017 Nov;38(11):805-816
pubmed: 28830733
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Immunol Rev. 2010 Sep;237(1):249-63
pubmed: 20727040
Cell. 2002 Apr;109 Suppl:S35-44
pubmed: 11983151
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
PLoS Pathog. 2020 Jul 29;16(7):e1008737
pubmed: 32726355
Exp Gerontol. 2020 Feb 22;134:110887
pubmed: 32092501
J Indian Inst Sci. 2020;100(4):793-807
pubmed: 33144763
Vaccine. 2000 Nov 22;19(7-8):862-76
pubmed: 11115710
Proc Natl Acad Sci U S A. 1980 Mar;77(3):1602-6
pubmed: 6966401
Nature. 1983 Apr 14;302(5909):575-81
pubmed: 6300689
BMC Immunol. 2008 Mar 16;9:8
pubmed: 18366636
Clin Infect Dis. 2021 Jan 27;72(2):301-308
pubmed: 33501951
Bioinformatics. 2017 Oct 01;33(19):3065-3071
pubmed: 28549079
J Inflamm Res. 2021 Apr 16;14:1487-1510
pubmed: 33889008
Aging (Albany NY). 2020 May 29;12(10):9959-9981
pubmed: 32470948
Annu Rev Immunol. 1994;12:991-1045
pubmed: 8011301
Protein Sci. 2003 May;12(5):1007-17
pubmed: 12717023
Bioinformatics. 2007 Jun 1;23(11):1371-7
pubmed: 17341499
Autoimmunity. 2011 Jun;44(4):261-70
pubmed: 21244330
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W509-12
pubmed: 18463140
BMC Bioinformatics. 2013 Apr 15;14:127
pubmed: 23586423
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
Int J Infect Dis. 2020 Oct;99:219-225
pubmed: 32758693
J Theor Biol. 2015 Jun 21;375:32-39
pubmed: 25445185
BMC Bioinformatics. 2009 Nov 25;10:387
pubmed: 19939270
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Annu Rev Immunol. 2003;21:305-34
pubmed: 12471050
Nature. 1966 Jul 16;211(5046):242-3
pubmed: 5965537
Nat Immunol. 2002 Sep;3(9):793-6
pubmed: 12205463
Bioinformatics. 2016 Feb 15;32(4):511-7
pubmed: 26515819
BMC Bioinformatics. 2008 Dec 12;9 Suppl 12:S22
pubmed: 19091022
Sci Rep. 2020 Jul 2;10(1):10895
pubmed: 32616763
AIDS Res Hum Retroviruses. 2004 Dec;20(12):1314-23
pubmed: 15650424
Front Cell Infect Microbiol. 2020 Oct 23;10:559209
pubmed: 33194799
Curr Opin Immunol. 2001 Feb;13(1):114-9
pubmed: 11154927
J Clin Invest. 2020 May 1;130(5):2202-2205
pubmed: 32217834
Front Immunol. 2019 Jul 03;10:1513
pubmed: 31338096
Bioinformatics. 2004 Jun 12;20(9):1388-97
pubmed: 14962912
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Appl Intell (Dordr). 2020;50(11):3913-3925
pubmed: 34764546
Immunology. 2018 Jul;154(3):394-406
pubmed: 29315598
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Nucleic Acids Res. 2020 Jan 8;48(D1):D783-D788
pubmed: 31722398
BMC Bioinformatics. 2007 Jul 04;8:238
pubmed: 17608956
BMJ. 2020 Jul 1;370:m2516
pubmed: 32611558
Curr Opin Immunol. 2007 Dec;19(6):658-64
pubmed: 17949964
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Comput Math Methods Med. 2019 Feb 03;2019:7525834
pubmed: 30863457
Nat Commun. 2020 Jul 30;11(1):3810
pubmed: 32733001
Rev Assoc Med Bras (1992). 2020 Apr;66(4):534-540
pubmed: 32578792
Int J Mol Sci. 2021 Mar 17;22(6):
pubmed: 33802761
Cancer Cell. 2020 Nov 9;38(5):661-671.e2
pubmed: 32997958
Front Immunol. 2019 Sep 25;10:2247
pubmed: 31608061
Immunogenetics. 2004 Mar;55(12):797-810
pubmed: 14963618
BMC Bioinformatics. 2016 Dec 22;17(Suppl 19):506
pubmed: 28155642
Ann Immunol (Paris). 1974 Jan;125C(1-2):373-89
pubmed: 4142565
Exp Cell Res. 1961 Dec;25:585-621
pubmed: 13905658
J Biomol Struct Dyn. 2021 Jul;39(10):3793-3801
pubmed: 32419646
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Infect Dis Poverty. 2020 Jul 8;9(1):85
pubmed: 32641121
PLoS One. 2010 Apr 16;5(4):e9862
pubmed: 20419125
Bioinformatics. 2005 Jun 15;21(12):2891-7
pubmed: 15817697